Patents Assigned to AstraZeneca
  • Composition 064
    Patent number: 8168221
    Abstract: A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide with mannitol and/or 5 microcrystalline cellulose is described.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: May 1, 2012
    Assignee: AstraZeneca AB
    Inventors: John David Blyth, Andrew John Day, Kieran James Lennon
  • ETHANOLAMINE SALT OF N- (3-METHOXY-5-METHYLPYRAZIN-2YL) -2- (4-[1, 3, 4-OXADIAZOLE-2-YL] PHENYL) PYRIDINE-3- SULPHONAMIDE
    Publication number: 20120101109
    Abstract: N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide ethanolamine salt and its uses are described.
    Type: Application
    Filed: July 25, 2011
    Publication date: April 26, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Catherine Good, Philip Hogan, Frank Montgomery
  • Process For Preparing [1S-[1-alpha, 2-alpha, 3-beta (1S*,2R*) 5-beta]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1,2-diol And To Its Intermediates
    Publication number: 20120101274
    Abstract: The present invention is directed to a process for preparing [1S-[1?,2?,3?(1S*,2R*),5?]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol and to intermediates useful in the process.
    Type: Application
    Filed: September 8, 2009
    Publication date: April 26, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Martin Hans Bohlin, Helena Hellström, Peter W. Johansson, Ulf G. Larsson, Mikaela Recknagel, Rhony Aufdenblatten, Andreas Weiss, Ursula Weiss
  • Compounds and their uses 708
    Patent number: 8163905
    Abstract: The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: April 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Stephen Brough, Richard Evans, Timothy Jon Luker, Piotr Raubo
  • Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
    Patent number: 8163724
    Abstract: The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: April 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Håkan Bladh, Frank Burkamp, Balint Gabos, Peter Hansen, Svetlana Ivanova, Karolina Lawitz
  • Process for the synthesis of piperidinyl sulphonate esters
    Patent number: 8163926
    Abstract: The present invention relates to a process for the manufacture of a compound of the Formula IIa: wherein R is a suitable sulphonate ester; from a (C1-C6)alkyl-4-piperidinecarboxylate compound of the Formula III:
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: April 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
    Patent number: 8163727
    Abstract: The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Timothy Jon Luker, Timothy Nicholas Birkinshaw, Rukhsana Tasneem Mohammed
  • Heteroaryl substituted benzothiazoles
    Patent number: 8163928
    Abstract: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: April 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Ylva Gravenfors, Catrin Jonasson, Jonas Malmstrom, Gunnar Nordvall, David Pyring, Can Slivo, Daniel Sohn, Peter Strom, David Wensbo
  • 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF
    Publication number: 20120094995
    Abstract: This invention relates to 2-aza-bicyclo[2.2.1]heptane compounds (and salts thereof), the process for making such a compound and pharmaceutical compositions comprising such a compound. The invention also relates to the use of the compounds for modulating the glycine transporter 1 (GlyT1) and for the treatment of psychosis, cognitive disorders, bipolar disorders, depression disorders, anxiety disorders, post-traumatic stress disorders and pain.
    Type: Application
    Filed: January 27, 2010
    Publication date: April 19, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Jeffrey Scott Albert, Donald Andisik, Cristobal Alhambra, Todd Andrew Brugel, Glen E Ernst, William Frietze, Lindsay Hinkley, Jeffrey Gilbert Varnes, Xia Wang, Hui Xiong
  • NOVEL COMPOUNDS
    Publication number: 20120095011
    Abstract: The invention provides compounds of formula in which R1, R2, R3 and R4 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Application
    Filed: December 7, 2011
    Publication date: April 19, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Andrew Pape, Andrew Thomas
  • Compounds
    Patent number: 8158820
    Abstract: The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: April 17, 2012
    Assignee: AstraZeneca AB
    Inventors: Roger Bonnert, Stephen Brough, Andrew Davies, Timothy Luker, Thomas McInally, Ian Millichip, Garry Pairaudeau, Anil Patel, Rukhsana Rasul, Stephen Thom
  • Dibenzothiazepine derivatives and uses thereof—424
    Patent number: 8158618
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: April 17, 2012
    Assignee: AstraZeneca AB
    Inventors: Dean Brown, James R. Damewood, Phil Edwards, James Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
  • 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy
    Patent number: 8158785
    Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: April 17, 2012
    Assignee: AstraZeneca AB
    Inventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
  • Quinazoline derivatives
    Patent number: 8153643
    Abstract: The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Patrick Ple, Frederic Henri Jung
  • Device and method for deaggregating powder
    Patent number: 8151793
    Abstract: A device for inhalation of at least one air stream carrying a dose of medicament powder is provided. The device includes a flow passage passing a powder-containing cavity. A part of said flow passage propagates along a generally flat surface region. The flat surface region includes a cavity opening into said powder-containing cavity. The passing of an air stream along said flat surface region and outside said cavity generates an eddy in the cavity and the generated eddy contributes to deaggregation of the powder in said cavity and emptying of the powder from said cavity. Furthermore, a shear driven cavity principle is used in conjunction with such a device and a method of releasing medicament powder.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: April 10, 2012
    Assignee: Astrazeneca AB
    Inventors: Orest Lastow, Johan Remmelgas
  • Metalloproteinase inhibitors
    Patent number: 8153673
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Metabotropic glutamate-receptor-potentiating isoindolones
    Patent number: 8153638
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Compounds
    Patent number: 8148373
    Abstract: The present invention relates to spirocyclic amide derivatives of the formula I, pharmaceutically acceptable salts thereof, a process for their preparation, pharmaceutical compositions containing them, and their use in therapy.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: April 3, 2012
    Assignees: AstraZeneca AB, Pulmagen Therapeutics (Synergy) Limited
    Inventors: Lilian Alcaraz, Nicholas David Kindon
  • Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286
    Patent number: 8148372
    Abstract: Compounds in accord with Formula I: wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: April 3, 2012
    Assignee: AstraZeneca AB
    Inventors: Joseph Cacciola, James Empfield, James Folmer, Angela M Hunter, Scott Throner
  • Salt I
    Patent number: 8148405
    Abstract: The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide benzoate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: April 3, 2012
    Assignee: AstraZeneca AB
    Inventors: Julien Giovannini, Bo-Goran Josefsson